HOLLISTON, Mass., Oct. 18, 2017 -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its third quarter 2017 after market trading hours on Thursday, October 26, 2017. A conference call to discuss the company's third quarter 2017 financial results and its operations is scheduled for that same date at 4:30 PM ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.
Participating in the call will be Jeffrey A. Duchemin, President and Chief Executive Officer; and Robert Gagnon, Chief Financial Officer of Harvard Bioscience. Investors can access the live conference call by dialing the following phone numbers: toll-free 1-800-708-4539, or international: 1-847-619-6396, and referencing the conference ID# 45846204.
The conference will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, log on to the webcast at:
http://investor.harvardbioscience.com/
and click on the Earnings Call icon. Financial information presented on the call, including the earnings release, will also be available on the investor relations section of the website.
If you are unable to listen to the live conference call, the webcast will be available on the Company's website through November 2, 2017.
To add this meeting to your calendar visit: http://investor.harvardbioscience.com/ and click “remind me”.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.
CONTACT: Corey Manchester Director, Finance and Investor Relations Tel: 508 893 8999


SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 



